FIBRES Trial

Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery

Excessive bleeding is a common complication of cardiac surgery that is associated with increased risk of morbidity and mortality, and higher associated costs.

An important cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which guidelines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate.

Although both products are plasma-derived, they have distinct features. Cryoprecipitate is not pure; in addition to its widely variable fibrinogen content (from 3-30 g/L per unit), it contains platelet microparticles, as well as coagulation factors VIII, XIII, and von Willebrand factor. In most cases it must be maintained and shipped in a frozen state and then thawed and pooled (typically 5-10 unit pools) before administration.

Fibrinogen concentrate is pathogen-reduced and purified; has standardized fibrinogen content (20 g/L), and is lyophilized, allowing for easy storage, reconstitution, and administration.

H3: Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery

FIBRES was a prospective, multicentre, randomised, phase III study comparing the haemostatic efficacy of fibrinogen concentrate (FC, fibryga®) with cryoprecipitate in patients ≥18 years who developed acquired fibrinogen deficiency during cardiopulmonary bypass surgery.

Create an Account to Keep Learning


You’ve unlocked an exclusive part of our content! To continue reading this blog and explore more evidence-based, practical guidance, please create an account or log in if you already have one.